Navigation Links
Cord Blood America CEO Matthew Schissler Interviewed on International Successes
Date:7/18/2011

LAS VEGAS, July 18, 2011 /PRNewswire/ -- Cord Blood America, Inc. (http://www.cordblood-america.com) (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that co-founder and CEO Matthew Schissler was interviewed by analyst Francis Gaskins about the Company's international successes.

The entire interview is available at: http://gaskinsco.com/cbai-7-15-11.mp3

Mr. Schissler said in the interview that as more research shows the usefulness of stem cells in therapies combating numerous diseases, more of the "raw material," the stored stem cells, will be needed.  He said that is one reason Cord Blood America is establishing an "international brand," with hubs in Argentina, Europe and China to become a worldwide leader in providing needed stem cells.

Cord Blood America's CEO said BioCells, Inc., its Argentina-headquartered stem cell company, has recently opened eight franchises in the same number of cities in that country, besides opening an office in Miami for Latin Americans in the U.S.  Sales have been strong in South America, Mr. Schissler said.  Stellacure GmbH, the Company's stem cell firm headquartered in Germany, is part of a broadbased strategy to be invested in small stem cell companies throughout the Continent, including in Spain and Italy, Cord Blood America's CEO said.

In the interview, Mr. Schissler also comments on the stem cell collection facility in China, in which Cord Blood America is a minority partner.

About Cord Blood America

Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.

CONTACT:
Paul Knopick
E & E Communications
949/707-5365
pknopick@eandecommunications.com

Safe Harbor:  This press release contains forward-looking statements.   Forward-looking statements, which involve assumptions and describe our future plans, strategies and expectations, are generally identifiable by use of the words "may," "will," "should," "expect," "anticipate," "estimate," "believe," "intend" or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned that such forward looking statements should not be construed as a guarantee or assurance of future performance or results. Actual events or results may differ materially from those discussed in forward-looking statements as a result of various factors.  In light of these risks and uncertainties, there can be no assurance that the forward-looking statements contained herein will in fact occur.  These forward-looking statements are based on current expectations, and the Company assumes no obligation to update this information. Readers are urged to carefully review and consider the various disclosures made by the Company in its Form 10-K and in the Company's other reports filed with the Securities and Exchange Commission that discuss certain of the risks and factors that may affect the Company and its business.


'/>"/>
SOURCE Cord Blood America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
2. Biotest Diagnostics Receives FDA Clearance for Full Line of Traditional Blood Bank Reagents
3. Limbs saved by menstrual blood stem cells
4. Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes
5. Human Trial Results Show Plant Extract Tops Drug at Regulating Blood Sugar Levels; Huge Market Seen for Newly Developed Food Additive Emulin™
6. No Blood Needed Thanks to Innovative Medical Technology
7. The Modern DeBakey VAD™ To Be Introduced For the First Time in the U.S. : HeartAssist 5™ Pediatric VAD Features Industry Exclusive Direct Blood Flow Measurement System
8. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
9. CORD:USE Cord Blood Bank is Proud to Announce that Cord Blood Pioneer and Leading Transplanter Dr. Eliane Gluckman has Joined its Team
10. American Red Cross Expands Agreement for Strategic Blood Management(TM) Services from Strategic Healthcare Group LLC
11. China Biologic Products Enters Into Agreement to Acquire 35% Interest in Xian Huitian Blood Products Co., Ltd. and Introduces Preliminary Guidance for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... Diego, California (PRWEB) , ... February 28, 2017 ... ... and supports high-growth, high-impact life science and biotechnology companies today announced it ... entrepreneurial communities, will be based out of Durham, NC and will begin work ...
(Date:2/28/2017)... , Feb. 28, 2017  ITL Limited ... company, supplier and strategic partner that provides innovative ... individual health management, formally announces its rebrand to ... name change is part of the Company,s unified ... launch of an integrated corporate website, ITLHealthGroup.com ...
(Date:2/28/2017)... , Feb. 28, 2017 Sangamo ... genome editing, today reported its fourth quarter and ... "Early this year we rebranded our ... clinical development of genomic therapies using our industry ... gene regulation and cell therapy," said Sandy ...
(Date:2/28/2017)... YORK , February 28, 2017 ... up for assessment are the following equities: ZIOPHARM Oncology Inc. ... AUPH ), Arena Pharmaceuticals Inc. (NASDAQ: ARNA ... These companies belong to the Healthcare sector, which was narrowly ... NYSE Health Care Index declining less than 0.1%, while shares ...
Breaking Biology Technology:
(Date:2/21/2017)... and PORTLAND, Ore. , Feb. ... the Avamere Family of Companies (Avamere Health Services, Infinity ... a six-month research study that will apply the power ... at senior living and health centers. By analyzing data ... to gain insights into physical and environmental conditions, and ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- RSA, ... that is designed to enhance fraud detection and ... in the RSA Fraud & Risk Intelligence Suite. ... to leverage additional insights from internal and external ... better protect their customers from targeted cybercrime attacks. ...
(Date:2/8/2017)... , Feb. 8, 2017 About Voice ... voice to match it against a stored voiceprint ... as pitch, cadence, and tone are compared to ... minimal hardware installation, as most PCs already have ... different transactions. Voice recognition biometrics are most likely ...
Breaking Biology News(10 mins):